title: Clinical significance of serum NM23-H1 protein in neuroblastoma.
abstract: We have previously reported that NM23 genes are overexpressed in various hematological malignancies and that serum NM23-H1 protein levels are useful for predicting patient outcomes. In this study we assessed the clinical implications of serum NM23-H1 protein on neuroblastoma. We examined serum NM23-H1 protein levels in 217 patients with neuroblastoma, including 131 found by mass-screening and 86 found clinically by an enzyme-linked immunosorbent assay, and determined the association between levels of this protein, and known prognostic factors or the clinical outcome. The serum NM23-H1 protein level was higher in neuroblastoma patients than in control children (P < 0.0001). Patients with MYCN amplification had higher serum NM23-H1 levels than those with a single copy of MYCN. Overall survival was assessed in the 86 patients found clinically, and was found to be worse in patients with higher serum MN23-H1 levels (> or = 250 ng/mL) than in those with lower levels (< 250 ng/mL; P = 0.034). The higher level of NM23-H1 was correlated with a worse outcome in patients with a single MYCN copy, or in those younger than 12 months of age. Serum NM23-H1 protein levels may contribute to predictions of clinical outcome in patients with neuroblastoma.
authors.affiliation: Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina-machi, Kitaadachi-gun, Saitama 362-0806, Japan. jkado@cancer-c.pref.saitama.jp
authors.forename: Junko
authors.initials: J
authors.lastname: Okabe-Kado
authors.forename: Takashi
authors.initials: T
authors.lastname: Kasukabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Honma
authors.forename: Ryoji
authors.initials: R
authors.lastname: Hanada
authors.forename: Akira
authors.initials: A
authors.lastname: Nakagawara
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kaneko
mesh_terms: D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018628:Gene Dosage; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000071447:N-Myc Proto-Oncogene Protein; D054778:NM23 Nucleoside Diphosphate Kinases; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D009687:Nuclear Proteins / Q000032:analysis; D009701:Nucleoside-Diphosphate Kinase / Q000097:blood*; D015513:Oncogene Proteins / Q000032:analysis; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D054778:NM23 Nucleoside Diphosphate Kinases; D009687:Nuclear Proteins; D015513:Oncogene Proteins; C517938:NME1 protein, human; D009701:Nucleoside-Diphosphate Kinase